full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
http://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for April, 2014

30
Apr

A high rate of incorrect biopsies has tangled the mid-stage results for Nymox Pharmaceutical’s experimental prostate cancer drug. Investigators say that NX-1207 reduced the rate of disease progression in patients, but they couldn’t determine if the drug hits its primary endpoint due to “the high percentage of false negative repeat biopsies in the active surveillance […]

30
Apr

Expecting to improve its odds of success for the experimental heart drug darapladib, a top drug prospect that failed its first late-stage test, investigators at GlaxoSmithKline have changed up the primary endpoint in the remaining Phase III study that reads out later this quarter. …read more Source: GlaxoSmithKline ups odds on heart drug hopeful with […]

29
Apr

France’s Transgene took a hit this morning after the biotech announced that Novartis had decided to pass on its option for the therapeutic cancer vaccine TG4010. But the CEO says he’s laying the groundwork for a late-stage study, confident that he can find another partner. …read more Source: Transgene takes a hit as Novartis shreds […]

29
Apr

Late last week, shares of CytoKinetics tanked when it put out the word that its lead drug for Lou Gehrig’s disease had missed the primary endpoint. Today, the biotech added that the ALS drug also missed a string of secondary endpoints, as well. There was, though, one bright spot: The drug achieved the secondary endpoint […]

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off